TCGA-K4-AAQO-01A-11R-A38B-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 11.79369251
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.410
- UV_RESPONSE_DN+0.390
- CHOLESTEROL_HOMEOSTASIS+0.320
- BILE_ACID_METABOLISM+0.310
- COAGULATION+0.260
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.260
- PANCREAS_BETA_CELLS+0.240
- KRAS_SIGNALING_UP+0.170
- KRAS_SIGNALING_DN+0.160
- FATTY_ACID_METABOLISM+0.140
Top 10 suppressed
- MYC_TARGETS_V2-0.480
- INTERFERON_ALPHA_RESPONSE-0.460
- DNA_REPAIR-0.370
- E2F_TARGETS-0.370
- GLYCOLYSIS-0.370
- MYC_TARGETS_V1-0.360
- G2M_CHECKPOINT-0.300
- INTERFERON_GAMMA_RESPONSE-0.300
- MTORC1_SIGNALING-0.300
- UNFOLDED_PROTEIN_RESPONSE-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-H4-A2HO-01A-11R-A180-07 | — | — | 0.842 |
| 2 | C3L-01890 | — | cohortA2 | 0.841 |
| 3 | ERR2208930 | — | — | 0.825 |
| 4 | SRR1447259 | GTEX | — | 0.824 |
| 5 | SRR8518381 | — | A | 0.814 |
| 6 | TCGA-UY-A8OD-01A-11R-A36F-07 | — | — | 0.813 |
| 7 | MBCProject_0063_T3A_RNA | — | A | 0.808 |
| 8 | SRR8613705 | — | A | 0.808 |
| 9 | SRR5088862 | — | — | 0.808 |
| 10 | TCGA-FD-A6TG-01A-11R-A32O-07 | — | — | 0.806 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.410 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.390 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.320 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.310 | Inavolisib | — uncovered |
| COAGULATION | 0.260 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.260 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.240 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.170 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.160 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.130 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.120 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.090 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.090 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.080 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.070 | Temsirolimus | — uncovered |
| ADIPOGENESIS | 0.060 | Inavolisib | — uncovered |